Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

To be considered for this study, you must be 12 years old or older and have a confirmed diagnosis of Hereditary Angioedema (HAE). You should have experienced at least three HAE attacks in the three months leading up to the study's first visit. It's also important that you have reliable access to your usual HAE emergency treatments, should you need them during the study.

There are also some reasons why you might not be able to join. For example, if your angioedema is due to a cause other than HAE, or if you've recently taken part in another clinical trial with an experimental drug. You can't have taken deucrictibant before, or certain other medications like ACE inhibitors or specific HAE preventative treatments recently. Pregnant or breastfeeding women, or those planning to become pregnant, are also unable to take part. We also need to check your liver and kidney health, and ensure there are no other significant medical conditions that might make participating unsafe for you.

If you join this study, your involvement would last for approximately 6 to 7 months in total. This includes an initial check-up period to confirm you meet all the study requirements. Once enrolled, you would take a study tablet (either deucrictibant or a placebo) once daily for 24 weeks, which is about six months. Throughout this time, you'll have regular visits to the clinic for assessments to check on your health and how the treatment is working. You will also be asked to keep a daily electronic diary to record information about any HAE attacks you experience and how you are feeling. After the 24 weeks of treatment, there will be a follow-up period of up to 4 weeks. Some participants may also have the option to continue into a separate, longer-term study if they wish.